Hydroxychloroquine

Results of Tabula Rasa HealthCare’s First Simulated Clinical Study on Proposed COVID-19 Treatments and Therapies is Published

Wednesday, August 12, 2020 - 4:02pm

In the study, TRHCs PPRDI first utilized TRHCs MedWise technology to determine each patients MedWise Risk Score (MRS), which is a predictive tool for adverse drug events (ADEs).

Key Points: 
  • In the study, TRHCs PPRDI first utilized TRHCs MedWise technology to determine each patients MedWise Risk Score (MRS), which is a predictive tool for adverse drug events (ADEs).
  • Next, five repurposed COVID-19 drugs (or drug combinations) were added, one at a time, to patient drug regimens.
  • The drug combinations included hydroxychloroquine, alone and in combination with azithromycin; chloroquine, alone and in combination with azithromycin; and lopinavir + ritonavir.
  • The results of this study validate the science behind our MedWise technology, states TRHC Chair and CEO Calvin H. Knowlton, Ph.D.

Hydroxychloroquine Case Is Filed in the Sixth Circuit by the Association of American Physicians & Surgeons (AAPS)

Tuesday, August 11, 2020 - 4:56pm

TUCSON, Ariz., Aug. 11, 2020 (GLOBE NEWSWIRE) -- On Monday the Association of American Physicians & Surgeons filed its Petition for Writ of Mandamus with the U.S. Court of Appeals for the Sixth Circuit on its lawsuit to end governmental interference with public access to hydroxychloroquine (HCQ).

Key Points: 
  • TUCSON, Ariz., Aug. 11, 2020 (GLOBE NEWSWIRE) -- On Monday the Association of American Physicians & Surgeons filed its Petition for Writ of Mandamus with the U.S. Court of Appeals for the Sixth Circuit on its lawsuit to end governmental interference with public access to hydroxychloroquine (HCQ).
  • Captioned In re Association of American Physicians & Surgeons, No.
  • 20-1743, AAPS explains to the Sixth Circuit why immediate action is necessary so that all Americans can benefit from the same prophylactic medication which President Trump successfully took to avoid contracting COVID-19.
  • The Deep State has improperly interfered with access to COVID-19 in three ways, AAPS explains in its extraordinary petition.

World's First Zinc Ionophore Oral Spray Launches in the EU

Saturday, August 1, 2020 - 3:00pm

MILAN, Aug. 1, 2020 /PRNewswire/ -- Dr ZinXhas launchedtheir Patent Pending Zinc + Hinokitiol Oral Sprayacross Amazon EU today.

Key Points: 
  • MILAN, Aug. 1, 2020 /PRNewswire/ -- Dr ZinXhas launchedtheir Patent Pending Zinc + Hinokitiol Oral Sprayacross Amazon EU today.
  • This is the first time a Zinc Ionophoreoral spray combination has been available to the EU market.
  • "A combination of Zinc Salts and Hinokitiol can be applied as an inexpensive, effective and safe alternative approach to fight respiratory viruses.
  • "-Dr Nikola Kolundzic, Kings College London
    Following wide publication and support from PresidentTrump for the use of a Hydroxychloroquine+ Zinc Combination, Zinc has come under increasing interest.

More Evidence Presented for Why Hydroxychloroquine Should be Made Available, in a New Court Filing by the Association of American Physicians & Surgeons (AAPS)

Wednesday, July 22, 2020 - 2:26pm

"Countries with underdeveloped health care systems are using HCQ early and attaining far lower mortality than in the United States, where [HHS and the FDA] impede access to HCQ."

Key Points: 
  • "Countries with underdeveloped health care systems are using HCQ early and attaining far lower mortality than in the United States, where [HHS and the FDA] impede access to HCQ."
  • "Citizens of the Philippines, Poland, Israel, and Turkey all have greater access to HCQ than American citizens do," observes AAPS General Counsel Andrew Schlafly.
  • AAPS rebuts arguments presented by the FDA, which implied that medications are approved as safe only for certain conditions.
  • In fact, HCQ and most medications have been approved without limitation, such that physicians can prescribe them for any off-label use.

Manuscript Describes How TLC’s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit and Serve as Potential Treatment for COVID-19

Wednesday, July 15, 2020 - 12:23pm

Hydroxychloroquine (HCQ) is an anti-malarial and anti-inflammatory drug that has been shown to inhibit SARS-CoV-2 infection in vitro and tested in clinical studies.

Key Points: 
  • Hydroxychloroquine (HCQ) is an anti-malarial and anti-inflammatory drug that has been shown to inhibit SARS-CoV-2 infection in vitro and tested in clinical studies.
  • However, recent clinical trials studying orally ingested HCQ have shown inconclusive results due to the extremely high doses required to achieve effective antiviral levels.
  • The manuscript describes a nonclinical pharmacokinetics study in which, comparing equivalent doses of inhalable liposomal HCQ to intravenous (to represent oral) unformulated HCQ, inhalable liposomal HCQ achieved increased exposure (~30-fold) and half-life (~2.5-fold) in the lungs while also achieving lower blood and heart exposure.
  • The manuscript, entitled A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Non-clinical Pharmacokinetic Study, has been submitted for publication and is currently under peer review.

New Study Shows That Hydroxychloroquine Saves Lives, States Association of American Physicians & Surgeons (AAPS)

Tuesday, July 7, 2020 - 7:07pm

The Association of American Physicians & Surgeons (AAPS) stated that these results should encourage widespread early use of this long-established drug to fight COVID-19.

Key Points: 
  • The Association of American Physicians & Surgeons (AAPS) stated that these results should encourage widespread early use of this long-established drug to fight COVID-19.
  • Researchers have been using HCQ too late, when patients may already have COVID-caused heart damage, and overdosing patients , states AAPS.
  • "If HCQ saves half the patients who would have died in hospital, then withholding HCQ is causing tens of thousands of preventable deaths," states AAPS.
  • The Association of American Physicians and Surgeons (AAPS) has represented physicians of all specialties in all states since 1943.

Lupus Foundation of America Survey Finds Over Half of Respondents Experienced Issues Accessing Hydroxychloroquine During Coronavirus Pandemic

Tuesday, June 23, 2020 - 3:00pm

WASHINGTON, June 23, 2020 /PRNewswire/ --In a new survey conducted by the Lupus Foundation of America, 55% of respondents taking antimalarials to manage their lupus reported having difficulty accessing their prescription for hydroxychloroquine or chloroquine, during March May 2020 of the coronavirus (COVID-19) pandemic.

Key Points: 
  • WASHINGTON, June 23, 2020 /PRNewswire/ --In a new survey conducted by the Lupus Foundation of America, 55% of respondents taking antimalarials to manage their lupus reported having difficulty accessing their prescription for hydroxychloroquine or chloroquine, during March May 2020 of the coronavirus (COVID-19) pandemic.
  • Hydroxychloroquine (Plaquenil) and Chloroquine (Aralen) are antimalarials, and hydroxychloroquine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of lupus and rheumatoid arthritis.
  • The survey also found that issues accessing hydroxychloroquine and chloroquine were prevalent across the country, with respondents in California, Florida, New York, Texas and Maryland as the top five states where people with lupus reported issues.
  • For more key findings from the survey, click here and for more information on the coronavirus and lupus visit lupus.org/coronavirus .

Preliminary Injunction Sought to Release Hydroxychloroquine to the Public, in the Lawsuit by the Association of American Physicians & Surgeons (AAPS)

Monday, June 22, 2020 - 5:22pm

Nearly 100 million doses of hydroxychloroquine (HCQ) were donated to these agencies, and yet they have not released virtually any of it to the public.

Key Points: 
  • Nearly 100 million doses of hydroxychloroquine (HCQ) were donated to these agencies, and yet they have not released virtually any of it to the public.
  • Millions of Americans fear attending political gatherings, religious services, and even large family get-togethers without the availability of early treatment if they were to contract COVID-19.
  • "Why does the government continue to withhold more than 60 million doses of HCQ from the public?"
  • The Association of American Physicians and Surgeons (AAPS) has represented physicians of all specialties in all states since 1943.

Researchers Overdosing COVID-19 Patients on Hydroxychloroquine, States Association of American Physicians & Surgeons (AAPS)

Wednesday, June 17, 2020 - 7:18pm

TUCSON, Ariz., June 17, 2020 /PRNewswire/ --Until President Trump suggested that hydroxychloroquine (HCQ, Plaquenil) might help COVID-19 patients, it was generally considered a very safe drug, observes the Association of American Physicians & Surgeons (AAPS).

Key Points: 
  • TUCSON, Ariz., June 17, 2020 /PRNewswire/ --Until President Trump suggested that hydroxychloroquine (HCQ, Plaquenil) might help COVID-19 patients, it was generally considered a very safe drug, observes the Association of American Physicians & Surgeons (AAPS).
  • It was approved by the FDA in 1955 and has been used by hundreds of millions of patients worldwide for malaria, lupus, and rheumatoid arthritis.
  • Apparently because of alarming media coverage, many patients are now expressing fear that HCQ is dangerous because of cardiac effects, states AAPS.
  • The Association of American Physicians and Surgeons (AAPS) has represented physicians of all specialties in all states since 1943.

Global Hydroxychloroquine Drugs Market (2020 to 2025) - Featuring Novartis AG, Sanofi & Amneal Pharmaceuticals Among Others - ResearchAndMarkets.com

Wednesday, June 17, 2020 - 3:23pm

The "Global Hydroxychloroquine Drugs Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hydroxychloroquine Drugs Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global hydroxychloroquine drugs market is projected to grow at a CAGR of 3.08% to reach US$1,174.129 million by 2025, from US$978.745 million in 2019.
  • Rising prevalence of chronic rheumatoid conditions, malaria, and lupus among the individuals is pushing the demand for hydroxychloroquine drugs.
  • However, as the hydroxychloroquine drugs are not so effective on all types of malaria, it hampers the market growth to some extent.